Manufacturing · New York, United States · 34,300 Employees
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The companys products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York.
View Company Info for Free
Who is Bristol-Myers Squibb
Top Competitors of Bristol-Myers Squibb
How does Giovanni Caforio compare against Competing Companies' CEOs?
CEO at Bristol-Myers Squibb
CEO effectiveness to drive business results
CEO effectiveness to drive business results
CEO at Johnson & Johnson
CEO at Merck
CEO at Pfizer
CEO at AstraZeneca
Bristol-Myers Squibb Org Chart
Bristol-Myers Squibb Email Formats
Bristol-Myers Squibb uses at least 5 email formats with first.last (ex. ) being used of the time
|Bristol-Myers Squibb Email Formats||Percentage|
|first + last||JohnSmith@bms.com|
Get Verified Emails
Bristol-Myers Squibb Company Metrics
Total Funding Amount
Most Recent Funding Amount
Number of Funding Rounds
Jul 18, 2022
Jul 27, 2017
Jan 11, 2014
Turning Point Therapeutics
Oct 06, 2013
Oct 12, 2012
Mar 31, 2012
See More Acquisitions & Subsidiaries
Top Companies in United States
Bristol-Myers Squibb News & Media
- Bristol-Myers Squibb Company's ( NYSE:BMY ) periodic dividend will be increasing on the 1st of February to $0.60, with...
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia....
- In this article, we will be taking a look at the 12 biggest financial scandals in U.S. history. To skip our detailed analysis, you can go directly to see the 5 biggest financial scandals in U.S. history. There are few things as serious as a major financial scandal, which don’t just threaten the reputation and […]
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability–High or.....
- PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
Frequently Asked Questions regarding Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its...